Abstract
Twenty-four clinicians, basic scientists and representatives of a patient advocacy organisation and pharmaceutical companies from 8 countries (Australia, England, France, Germany, Italy, Switzerland, Turkey, USA) gathered in Naarden, The Netherlands, to discuss the group of neuromuscular disorders caused by the deficiency of collagen type VI (ColVI), collectively termed ColVI-related myopathies. This meeting focused on three main areas: (1) the great heterogeneity observed at the genetic and clinical levels and the resulting complexity of the molecular diagnosis; (2) the pathophysiological mechanisms linking mutations in the COL6A genes to muscle pathology; (3) the current strategies for therapeutic interventions which have led to the design of upcoming clinical trials. Two sessions were also dedicated to existing and future databases, and to outcome measures.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
